BCMA CAR-T cell therapy / Innovative Cellular Therapeutics - LARVOL DELTA

The BCMA CAR-T Co-developed by Innovent and IASO Was Granted Breakthrough Therapy Designation by the NMPA for the Treatment of Relapsed/Refractory Multiple Myeloma (PRNewswire) - "Innovent Biologics...today jointly announce that the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) has granted Breakthrough Therapy Designation (BTD) for the investigational chimeric antigen receptor (CAR)-T cell therapy co-developed by Innovent and IASO (Innovent development code: IBI326, IASO development code: CT103A), for treatment of relapsed/refractory multiple myeloma...The BTD designation for IBI326 is based on the results observed in ongoing Phase 1/2 study..."

Non-US regulatory • Hematological Malignancies • Multiple Myeloma • Oncology